| 摘要 |
The postresectional tumor recurrence rate is high in patients with hepatocellular
carcinoma (HCC). To improve the long-term outcome for HCC patients after
potentially curative resection, effective measures in reducing the recurrence risk are
mandatory. The aim of adjuvant therapy is to decrease the incidence, or delay tumor
recurrence, or to prevent new tumor formation in the liver remnant after hepatic
resection. Various therapeutic modalities, including transarterial chemoembolization,
systemic and loco-regional chemotherapy, I-131-lipiodol transarterial
infusion, immunotherapy and treatment with anti-angiogenesis agents have been
evaluated in the adjuvant setting. A review of the current evidence of adjuvant
therapy in HCC patients indicates that the role of adjuvant therapy after hepatic
resection for HCC patients has not been well established. Further randomized
controlled studies are needed to confirm efficacy of the adjuvant protocols. |
